Jesi

Researchers are evaluating how well guselkumab works to improve symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, by using musculoskeletal ultrasound MSUS in a real-world setting. This observational study aims to collect data from routine clinical practice to better understand treatment effects in participants who have active psoriatic arthritis and meet specific clinical and imaging criteria. Participants with a confirmed diagnosis of psoriatic arthritis who are treated with guselkumab according to their usual clinical care will be enrolled. No study drug is provided by the trial instead, the study collects data available from standard care, including ultrasound exam results. Participants will be asked about their health and well-being during the study. The study includes baseline and follow-up assessments up to 52 weeks to monitor disease activity and response to treatment. During the study, participants will undergo musculoskeletal ultrasound evaluations and clinical assessments at various time points, including baseline, week 12, week 24, and week 52. Researchers will track outcomes such as reduction in synovitis scores, disease activity indexes, pain levels, physical function, and treatment persistence. The study also monitors adverse events. Participation involves routine clinical visits and data collection over approximately one year to observe guselkumab treatment effects in real-world use.

Researchers are evaluating a mobile health m-health solution designed to support self-management skills in adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. This randomized clinical trial compares the use of the personalized m-health tool integrated with the Electronic Patient Record EPR against usual diabetes care, focusing on changes in glycated hemoglobin HbA1c levels over an 18-month period. The study aims to enhance patients abilities to manage their condition through technology combined with healthcare collaboration. Participants are randomly assigned to one of two groups the treated group receives regular care plus access to the m-health solution, while the control group continues with standard care alone. The m-health solution includes mobile apps for tracking health data such as blood sugar, lifestyle habits, and diet, receiving alerts and motivational messages, communicating with healthcare professionals, and accessing educational materials. Healthcare providers will monitor patient data through an integrated platform and communicate as needed. The intervention begins at diabetic centers and continues at participants homes. Participants will undergo evaluations at the start and at 6, 12, and 18 months, including clinical assessments, questionnaires, and data collected from the m-health solution. Researchers will assess changes in diabetes severity, medication adherence, lifestyle habits, self-efficacy, quality of life, and the usability and satisfaction with the m-health tool. There are no additional visits or lab tests beyond usual care. The study includes cost-effectiveness analysis and gathers participant feedback to understand their experience with the intervention.

Obstructive Sleep Apnea OSA is a common sleep-related breathing disorder linked to serious health risks including heart, brain, and metabolic diseases. It has a high prevalence and worsens if untreated, contributing to increased mortality even in mild cases. European studies have shown varied symptoms and complications across regions, but detailed data for the Italian population is lacking. This study aims to better understand OSA in Italy by assessing different physiological and clinical patterns, its association with other health conditions, and creating a long-term patient database. The study collects clinical, sleep study, and treatment data from patients suspected of having OSA at Italian Sleep Centers. A clinical questionnaire will standardize data collection, and a feasibility study on 100 patients will be conducted. Additional tests include EKG, spirometry, blood pressure monitoring, blood chemistry, and assessments of sleepiness, cognitive function, and anxietydepression. A web platform will securely store anonymous patient information. Participants will undergo polysomnography after enrollment to confirm OSA. Data will be collected on apnea-hypopnea index and oxygen saturation at enrollment. Researchers will analyze OSA severity, associated metabolic and cardiovascular risks, and different clinical patterns. The study will develop screening questionnaires and establish a registry for ongoing follow-up to support preventive health strategies in Italy. Participation duration varies, with data collected at enrollment and follow-up planned.